Observes patients with heart failure using the WiSE System device
Watches how the WiSE device performs in adults with heart failure.
Key facts
- Who runs it
- EBR Systems, Inc.
- Where
- Ann Arbor, Austin, Charleston, Charlottesville, Cleveland, Hershey, Jonesboro, Kansas City, Mesa, Naples, New York, and Scottsdale, United StatesSee the 12 sites
- Trial code
- Registry title
- The WiSE®-UP Study (The WiSE System Utilization & Performance Study)
- Status
- Recruiting
- People taking part
- 320 people, planned
- Started
- 3 Nov 2025
- Expected to end
- 30 Sept 2032
- Type of study
- Observational
- Treatments tested
- The Wise System
- Record updated
- 16 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with heart failure who are planned to receive the WiSE System and passed the acoustic window screening.
- Age
- 22 years or older
- Sex
- All sexes can join
Main reasons for not taking part
- Not planning to receive a WiSE System or did not pass the acoustic window screening
- Taking part in another drug or device study that could confuse the results
- Life expectancy of 1 year or less
- Not able to be reached for follow-up
- Cannot give written consent, or taking part is not allowed by local law
The registry criteria, word for word
Show all 6 criteriaShow less
Other criteria
- Patient or legally authorized representative can provide written authorization and/or consent per institution requirements
- Patient is intended to receive a WiSE System and passed the acoustic window screening
- Patient who is, or will be, accessible for follow-up
- Participation is not excluded by local law
- Patient is not enrolled in a concurrent drug and/or device study that may confound the Registry results
- Patient life expectancy >1 year
Where in United States
- University of MichiganAnn Arbor, United StatesContact: Kirsta BrayTaking people
- Texas Cardiac Arrhythmia Research FoundationAustin, United StatesContact: Deb CardinalTaking people
- MUSCCharleston, United StatesContact: Krista SzymanskiTaking people
- UVACharlottesville, United StatesContact: Abbey FergusonTaking people
- Cleveland Clinic FoundationCleveland, United StatesContact: Danielle LiggettTaking people
- Penn State HealthHershey, United StatesContact: LIsa FoxTaking people
- Arrhythmia Research Group (St. Bernards Hospital)Jonesboro, United StatesContact: Kayla RubinoTaking people
- St. Luke's Hospital of Kansas CityKansas City, United StatesContact: Susan EhlertTaking people
- CardioVascular Associates of Mesa (CVAM)Mesa, United StatesContact: Adam GitkinTaking people
- Naples Community HospitalNaples, United StatesContact: Linda PastoriousTaking people
- Weill Cornell MedicineNew York, United StatesContact: Ruwanthi J PereraTaking people
- Honor HealthScottsdale, United StatesContact: Kathrina SpencerTaking people
About the trial
What the trial wants to find out
Observe to understand product performance, including patient safety, clinical outcomes, and CRT response information associated with the use of the market-released WiSE System
The group in the trial
- Single-arm, prospective, multicenter, observational study.
Market-released WiSE System approved for commercial release with a market-released co-implanted system are eligible.
Treatment: The Wise System
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- The WiSE®-UP Study (The WiSE System Utilization & Performance Study)
- Plain-language title
- Observes patients with heart failure using the WiSE System deviceGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 16 October 2026